UNSPSC 51402602: Ocinaplon

This classification denotes an anxiolytic with the molecular formula C17H11N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H6KVC5E76, chemically known as 2-pyridinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl)methanone but generally known as ocinaplon, which bears US NIH Compound Identifier 216456. European Medicines Agency schedules Ocinaplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09398MIG.

UNSPSC 51402602 Ocinaplon, a Commodity code, covers pharmaceutical products and drug-related interventions procured by state and local health agencies. Recent solicitations show state and local governments buying naloxone (opioid reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of participating state and local facilities. The work spans direct product procurement with quarterly or ongoing delivery cycles, vendor qualification requiring FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and contractual relationships with authorized pharmaceutical wholesalers.

Recent activity concentrates in Florida and Minnesota. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026, and awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence solicitation regarding direct-to-manufacturer pharmacy benefit programs, signaling exploratory procurement strategy development rather than immediate product procurement.